Additionally, our research suggests that antagonising the BD1 domain of Brd4 may not be as innocuous as previously believed, as its delayed side effects, such as accelerated ageing or age‐related neurodegenerative diseases, may manifest over time. The gene discussed is BRD4; the disease is age.